Biotech | August 06, 2021
Mark W. Womack is the new CEO of Stelis Biopharma
He will be stationed at the company HQ in Bengaluru, India
He will be stationed at the company HQ in Bengaluru, India
Innovative solutions and a deep understanding of the market makes this a unique combination
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina
The study was conducted in patients with mild to moderate COVID-19
Subscribe To Our Newsletter & Stay Updated
